anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study is planned to investigate the acute effects of forward and backward walking on physical functions such as static and dynamic balance and cognitive functions such as attention, concentration, memory, processing speed, visual structuring skills, calculation and orientation. 50 healthy individuals were randomly divided into three groups for the study. The groups were divided into Backward Walking Exercise Group (GYE) (n=17), Forward Walking Exercise Group (FWE) (n=16) and Control Group (CG)(n=17). Before treatment for all three groups; sociodemographic and clinical data with the sociodemographic information form, physical activity levels with the International Physical Activity Survey Short Form, pain severity with the Visual Analog Scale (VAS), fatigue levels with the Borg Scale, the person's selective attention capacity and skills, processing speed and general executive processing abilities. Stroop Test with TBAG Form to evaluate executive functions such as working memory, complex attention, planning and set shifting, with Trail Making Test, evaluation of dynamic balance, neuromuscular control and movement asymmetries with Y-Balance Test, static balance, postural stability evaluation on One Leg It was evaluated with the Standing Test. The GYE group completed a 25-minute backward walking exercise session, the FWE group completed a 25-minute forward walking exercise session, and the control group completed a 30-minute sitting rest between evaluation tests. After the exercises, there were significant differences in parameters such as attention, processing speed, concentration and maintenance of attention, working memory, planning, static and dynamic balance, and in the comparison between groups, significant differences were found in static balance and postural control (p\<0.05). It was observed that individuals in the backward walking group showed better improvements in some parameters after walking. However, these results need to be supported by future studies.
Compositions and methods for improving the nutritional and physiological status of a woman and her child during all stages of pregnancy are provided herein. This includes pre-conceptional women, pregnant women, and post-natal women (both lactating and non-lactating mothers). The compositions are particularly useful for the neurological, visual, and cognitive development of an embryo, fetus, or infant and the nutritional and physiological well-being of the mother, fetus, and infant. The compositions contain one or more folates, such as a reduced folate and/or folic acid, and one or more essential fatty acids (EFA), such as an omega-3 and/or omega-6 fatty acid. The addition of the essential fatty acid improves upon the folate containing nutritional preparations described in the prior art. The one or more folates and essential fatty acid may be administered together or in separate dosage units. The one or more folates may be selected from folic acid/folate, one or more reduced folates, or a combination of folic acid/folate and one or more reduced folates. The reduced folate is preferably 5-methyltetrahydrofolate, and most preferably 5-methyl-(6S)-tetrahydrofolic acid. The essential fatty acid is preferably an omega-3 fatty acid, and is preferably docosahexenoic acid (DHA) derived from a vegetarian or non-fish source. The compositions may optionally contain other vitamins, minerals, and ingredients, such as, emollient laxatives-all defined herein as “optional or other ingredients”.
The neonate was taken to the neonatal unit and monitored with a pulse-oximeter before, during and after the procedure. The neonate was swaddled, administered 1 mL of oral sucrose, and allowed to suck for 2 minutes prior to the procedure. The neonate also had a 7 x 7 cm gauze pad with 1 drop (43.75 mg) of 100% pure LEO (Pranarôm España S.L.) placed 2 cm under their nose for 2 minutes prior to starting the frenotomy and for the duration of the procedure.
5.1 Hypersensitivity Reactions   
Fatal and severe hypersensitivity reactions, including anaphylaxis, have occurred with intravenous or intramuscular administration of Phytonadione Injectable Emulsion. Reactions have occurred despite dilution to avoid rapid intravenous infusion and upon first dose. These reactions have included shock, cardiorespiratory arrest, flushing, diaphoresis, chest pain, tachycardia, cyanosis, weakness, and dyspnea. Administer Phytonadione Injectable Emulsion subcutaneously whenever feasible. Avoid the intravenous and intramuscular routes of administration unless the subcutaneous route is not feasible and the serious risk is justified [see DOSAGE AND ADMINISTRATION (2.1)].

5.3 Cutaneous Reactions   
Parenteral administration of vitamin K replacements (including Phytonadione Injectable Emulsion) may cause cutaneous reactions. Reactions have included eczematous reactions, scleroderma-like patches, urticaria, and delayed-type hypersensitivity reactions. Time of onset ranged from 1 day to a year after parenteral administration. Discontinue Phytonadione Injectable Emulsion for skin reactions and institute medical management.
PURPOSE:To obtain a dental filler effective for eliminating the odor and bitter taste in the oral cavity generated by an agent used in combination or caused by the grinding of tooth and applying fragrance to the oral cavity to suppress the disagreeable feeling by adding a flavoring agent or a seasoning agent to a filler such as a sealing agent. CONSTITUTION:A filler such as a sealing agent for filling and sealing the ground part of tooth in the case of applying a prosthesis, denervation of tooth and treatment of tooth is compounded with a flavoring agent (e.g. herb extract, strawberry extract, banana extract, menthol extract and extract of Chinese herb drug), a seasoning agent (e.g. palatinose) or a seasoning and flavoring agent (e.g. vanilla extract). The disagreeable odor generated in the oral cavity by the above-mentioned various factors and the bitter taste, etc., of the drug can be eliminated by the above flavoring agent and seasoning agent and, at the same time, excellent fragrance and taste are applied to the oral cavity to improve the disagreeable feeling of patients.
The invention relates to the medical field, and in particular, to protein complexes and application thereof for the correction of autoimmune processes in human or animal bodies and also to a research of biochemical mechanisms of diseases with angiogenesis disorders. The protein complexes claimed comprise an antigen and an effector portion attached thereto wherein said antigen presents an angiogenic factor. An angiogenic factors of a protein complexes could be both pro-angiogenic and anti-angiogenic. An effector portion can either show of immunomodulating activity, or provide the specific influence on a target immunocompetent cells Moreover, it can be made in the form of a polymer carrier for depleting of target autoantibodies and immunocompetent cells. There are also claimed the use of new protein complexes, the new methods of treatment of diseases with angiogenesis disorders and a new method and a new test-system for monitoring of angiogenesis disorders for use in the above methods of treatment. The inventors are emphasizing the role of autoimmune mechanism in origin of malignant growth and the importance of subject of the invention for early cancer diagnostics, prevention and treatment
BACKGROUND: The utility of preoperative abdominal ultrasonography (US) in evaluating patients with obesity before metabolic bariatric surgery (MBS) remains ambiguously defined.
METHOD: Retrospective analysis whereby patients were classified into four groups based on ultrasound results. Group 1 had normal findings. Group 2 had non-significant findings that did not affect the planned procedure. Group 3 required additional or follow-up surgeries without changing the surgical plan. Group 4, impacting the procedure, needed further investigations and was subdivided into 4A, delaying surgery for more assessments, and 4B, altering or canceling the procedure due to critical findings. Machine learning techniques were utilized to identify variables.
RESULTS: Four thousand four hundred eighteen patients' records were analyzed. Group 1 was 45.7%. Group 2, 35.7%; Group 3, 17.0%; Group 4, 1.5%, Group 4A, 0.8%; and Group 4B, 0.7%, where surgeries were either canceled (0.3%) or postponed (0.4%). The hyperparameter tuning process identified a Decision Tree classifier with a maximum tree depth of 7 as the most effective model. The model demonstrated high effectiveness in identifying patients who would benefit from preoperative ultrasound before MBS, with training and testing accuracies of 0.983 and 0.985. It also showed high precision (0.954), recall (0.962), F1 score (0.958), and an AUC of 0.976.
CONCLUSION: Our study found that preoperative ultrasound demonstrated clinical utility for a subset of patients undergoing metabolic bariatric surgery. Specifically, 15.9% of the cohort benefited from the identification of chronic calculous cholecystitis, leading to concomitant cholecystectomy. Additionally, surgery was postponed in 1.4% of the cases due to other findings. While these findings indicate a potential benefit in certain cases, further research, including a cost-benefit analysis, is necessary to fully evaluate routine preoperative ultrasound's overall utility and economic impact in this patient population.
Those randomized to have gonadotropins/IUI treatments first will initiate therapy with two cycles of the fertility injections called FSH or gonadotropins combined with (IUI) intrauterine insemination. If not pregnant after 2 IUI cycles, the couples will then proceed to IVF.
The invention relates to traditional Chinese medicine for curing hepatitis B, which is characterized by comprising snake meat, soybean flour, snake blood, egg white, snake bone, snake bile, and starch and the like. The formulation and ratio of flocculent dosage are as follows: snake meat 24%, soybean flour 6%, snake blood 3%, egg white 7%, snake bile 15 % and starch 15%. The invention has short curing time, 40 days for curing HbsAg+/eAg+/cAb+ and HbsAg+/eAb+/cAb+, and no more than two months for curing cirrhosis. As treatment course is short and effect shown is fast, daily behavior and work can not be affected. Complete recovery can be ensured as long as patients take proper doses of medicament on time and pay attention to other life habits. Patients with cirrhosis and HbsAg+/eAg+/cAb+ and HbsAg+/eAb+/cAb+ can be completely cured only by spending 2000 RMB. The formulation of the invention is proved by recovery examples of nine chemical examinations for liver function of patients with cirrhosis and, HbsAg+/eAg+/cAb+ and HbsAg+/eAb+/cAb+, and furthermore rebound and recurrence do not happen after recovery, and antibody can be produced naturally without injecting preventive inoculation.
The UK FSHD Patient Registry (https://www.fshd-registry.org/uk/) recruits any individual, from anywhere within the United Kingdom, with a diagnosis of FSHD. The registry is sponsored by Muscular Dystrophy UK. Participants may be referred to the registry by health care professionals, genetic testing/laboratory centres who are aware of the registry etc. Alternatively, a participant may have discovered the registry via promotional activities or by their own online searches. After completing the consent process, participants are able to enter information on to the registry platform (note all forms are available to view on the registry website before joining the registry). This is an ongoing database and all participants are invited to update their information on an annual basis.

The database is designed to be self reporting, however where specialised clinical or genetic information is required, the neuromuscular specialist in charge of the participants care can be invited to provide some additional information. The participant is able to select a health care provider from a pre-populated list at registration stage, if they wish to (optional feature). This information is included in the patient information and consent. Relevant R\&D approval has been recieved.
Access to the peritoneal cavity will be performed similar to vaginal surgery by a circular incision around the cervix, anterior and posterior colpotomy and transsecting the sacro-uterine ligaments. The vNOTES port will be placed to get access to the abdominal cavity and a pneumoperitoneum will be created. After positioning in 20o degree Trendelenburg laparoscopic instruments will be introduced. The peritoneal cavity and ureters are inspected. The hysterectomy is performed by dissecting from caudally to cranially. The fallopian tubes will be removed elective after counselling in the outpatient clinic and the ovaries will be removed on indication only. Haemostasis is checked and the vNOTES port and the uterus are removed trans-vaginally and the pneumoperitoneum is deflated. The vaginal cuff will be closed using a running Vicryl-1 suture. The urinary bladder catheter will be removed directly postoperative.
The reduction of the CPAP pressure begins at the morning ward round and the pressure is reduced in steps with 1 cmH2O maximum once a day. Each time the pressure is to be reduced the infant needs to be evaluated according to the inclusion criteria and only if these are still met, will the pressure be reduced. When a CPAP pressure at 4 cmH2O is reached the infant is treated with this pressure for 24 hours and then the CPAP is discontinued. Infants are considered successfully weaned if they are off CPAP for three days.
PURPOSE: A novel butylactone derivative or Aspergillus terreus extract is provided to ensure radical removal activity and to be used in an anti-oxidative composition, health food composition, and cosmetic composition. CONSTITUTION: An extract of Aspergillus terreus is isolated from Aspergillus terreus mycelium culture using water, C1-C4 low alcohol, a mixture solvent thereof, or an organic solvent. The alcohol is methanol, ethanol, or butanol. The organic solvent is chloroform or ethyl acetate. The butyrolactone derivative is denoted by chemical formula 1. A method for preparing the butyrolactone derivative of chemical formula 1 comprises: a step of extracting the Aspergillus terreus mycelium culture; a step of performing silica gel column chromatography to obtain a first fraction; a step of performing Sephadex LH-20 column chromatography to obtain a second fraction; a step of performing reversed-phase chromatography.
Patients will receive single shot L1-L2 PVB before undergoing GA Full monitoring with ECG , NIBP , puls oximetry will be applied. The level between L1 and L2 will be identified using U/S as well as transverse processes depth. Insertion points will be marked 2.5 cm lateral to the superior aspect of corresponding spinous processes, A 22-gauge Tuohy needle will be advanced until it made contact with the transverse process. The needle will be withdrawn slightly and walked off caudally to an additional depth of 1 cm. Once this is reached, 20cc of bupivacaine 0.25% will be injected slowly To control intraoperative blood pressure, fentanyl will be used as well as hypotensive drugs ( propranolol and nitroglycerine and the total dose will be recorded.
The present invention relates to pharmaceutical compositions for the sustained release of pharmacologically active compounds, and methods of their manufacture and use. The pharmaceutical compositions contain microcrystals of pharmacologically active compounds which are encapsulated within a phospholipid layer which contain a unique combination of phospholipids. The pharmaceutical compositions may be rendered suitable for injection. The microcrystals are of varying sizes. At least 50 percent of the microcrystals are from 0.5 μm and 3.0 μm in diameter, at least ten percent of the microcrystals are from 3.0 μm to 10 μm in diameter, and the composition may contain microcrystals which are greater than 10 μm in diameter. Methods of manufacturing the composition are disclosed, as well as various methods of administration.
PURPOSE:To suppress elution of calcium ion into water as little as possible by adding and mixing a specified compd. into calcium hydrogenphosphate or its suspension liquid. CONSTITUTION:Calcium hydrogenphosphate is suspended in water, to which a single or mixture compd. selected from among oxalic acid, sodium oxalate, sodium potassium oxalate, potassium oxalate, magnesium oxalate, calcium oxalate, sodium silicate, potassium silicate, magnesium silicate, magnesium calcium silicate and calcium silicate is mixed solely or in combination by <=30wt.% at 10-100 deg.C. After the mixture is stirred for 0.5 to 50 hours, filtered and dried, or, these inorg. salts are mixed in a dry state to calcium hydrogenphosphate so that the surface of calcium hydrogenphosphate is coated with an inorg. salt having negative ions with low solubility than calcium hydrogenphosphate when the inorg. salt is changed into calcium salt. Thus, elution of calcium ion is suppressed. The obtd. calcium hydrogenphosphate is useful as an abrasive for toothpaste.
The pilot trial will utilize a cluster randomized controlled design to assess the feasibility, acceptability, and preliminary effectiveness of the house chat model as a grassroots approach to lifestyle intervention delivery in a community setting. Two wards will be randomly assigned to either intervention or a delayed intervention control. A total of 10 HCL will be recruited and trained across the two wards (5 in the intervention ward and 5 in delayed intervention ward). HCL will recruit members of their social network (N=80, \>18 years of age) to participate in a 12-week lifestyle intervention delivered via weekly group meetings in the HCL's homes. The primary goal is to understand the feasibility and acceptability of this novel approach to intervention delivery, and as such, process data on recruitment, training, fidelity of intervention delivery, and satisfaction with the sessions will be collected on a weekly basis. In addition, in-person assessment visits will take place at 0, 12 weeks (post-treatment) and 24 weeks (follow up) to determine the preliminary effectiveness of this intervention to promote positive changes on behavioral risk factors (physical activity and diet) and adiposity (weight and waist circumference). Satisfaction will be assessed in-person at 12 weeks (post-treatment) via surveys and an exit interview. In addition, The investigators will employ a mixed methods approach (process data, surveys, in-depth interviews with HCL and focus groups with participants) to assess factors that might promote and / or interfere with sustainability over long-term follow up to inform our future clinical trial.
Dolichoectatic vertebrobasilar (DVB) aneurysms are fusiform in geometry and often large (\< 10 cm) in size limiting traditional microsurgical clipping or endovascular coiling strategies. Collectively, DVB aneurysms represent ≤ 0.01% of all aneurysms (\~ 600 US) and, consequently, their study is limited to a few small series. Despite their rarity, the location and geometry of DVB aneurysms make surgical intervention, microsurgical or endovascular, nearly uniformly fatal. Therefore, most DVB aneurysms are observed providing greater insight into their natural history than many more surgically amenable aneurysms. One series noted 28% of patients manifesting any neurological deficit, ischemic or hemorrhagic, over a 4 year interval with an overall mortality rate of \~ 20%.

Tumor necrosis alpha (TNFα). From the many implicated genetic pathways in aneurysm formation, tumor necrosis alpha (TNFα) has been noted a pivotal actor. In pre-clinical studies, the ability to inhibit TNFα induction prevents aneurysm rupture and even aneurysm growth altogether. In humans, TNFα inhibitor therapy has proven effective for many types of vascular inflammation including carotid wall thickening in the setting of rheumatoid arthritis. Over 12- and 24-month intervals, others have demonstrated significant decreases in carotid intima-media thickness in patients taking the TNFα inhibitor, infliximab. Furthermore, infliximab therapy has proven effective in refractory Kawasaki's disease, a condition characterized by post-infectious coronary artery inflammation in children. There is also evidence that infliximab therapy is effective in treatment of IVIG-refractory Kawasaki's disease including regressing coronary aneurysms. Despite the multitude of agents and indications both on and off-label, TNFα inhibitor therapy has not been used for the treatment of brain aneurysm.
The present technology may include combining different non-synthetic products to form a broad-spectrum antiviral supplement that inhibit or kill viruses. The antiviral supplement can be added to a shake, juice, or food to include antiviral properties. In one embodiment, the supplement may be configured to be admixed in the product. The product may include at least four ingredients selected from a first group, a second group, and a third group. In particular, the supplement may include at least four ingredients with two ingredients selected from the first group. Sweeteners including honey, artificial honey, molasses, or syrup combined with natural preservatives can also be used to provide broad-spectrum antiviral protection.
Background: Opioid misuse and substance use disorders (SUDs) including opioid use disorder (OUD) are common and negatively impact quality of life. Hospice clinicians' experiences with these conditions have not been well described. Objectives: We sought to explore hospice clinicians' knowledge, practices, and comfort caring for patients with opioid misuse (e.g., a pattern of unsanctioned opioid use escalation, or concurrent illicit substance use) and SUDs. Design: We recruited hospice clinicians in the United States via national hospice and palliative care organizations to complete an online survey designed by the study authors and pilot tested with an interdisciplinary group of current/former hospice clinicians. Results: One hundred seventy-five clinicians (40% nurses, 40% physicians, 16% nurse practitioners) responded to the survey; most had cared for two or more hospice patients with opioid misuse or SUD in the past month. The majority felt confident identifying opioid misuse (94%) and taking SUD histories (79%). Most (62%) felt it is their role to treat hospice patients for SUD, though 56% lacked comfort in using buprenorphine for OUD treatment. While the majority felt it is their role to treat pain in hospice patients with SUDs (94%) and that hospice can help patients with SUDs (94%), many were not comfortable managing pain in patients taking buprenorphine (45%) or naltrexone (49%) for SUDs. Most felt comfortable managing pain in patients taking methadone for SUD (73%). Conclusions: Opioid misuse and SUD are common in hospice. Though clinicians are comfortable taking relevant histories, they feel less comfortable managing patients' opioid misuse or SUD, or these patients' pain.
A 10 ml syringe with 2 mg/ml of methadone will be prepared and and study drug will be administered as intravenous bolus dose (0.15 mg/kg treatment weight (height (cm) - 100)). The study drug will be administered 1 hour prior to expected extubation.
Classic TLIP block After providing aseptic conditions, the high frequency linear US probe will be covered with a sterile sheath, and a 50 mm block needle will be used. The ultrasound probe will be placed vertically at the level of the L3 vertebra. After visualizing the guiding point spinous process and interspinal muscles, the probe will be moved laterally to visualize the longissimus and multifidus muscles. By using the in-plane technique, the block needle will be directed from medial to lateral, and after reaching the interfacial area between the longissimus and multifidus muscles, the block area will be confirmed by administering 5 ml of serum physiologically. Then, 20 ml of 0.25% local anesthetic will be administered. The same procedure will be applied to the other side. A total of 40 ml of local anesthetic solution will be used.
Subjects inserted with the AtaCor StealthTrac Lead Model AC-1020. This was the second model evaluated in the study.